The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms.
...
A randomized clinical trial evaluated whether behavioral science–informed electronic health record interventions can improve deprescribing rates of potentially inappropriate medications among older adults...
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
A systematic review and meta-analysis evaluated whether pharmacist-led deprescribing interventions reduce polypharmacy and potentially inappropriate medications among older adults across care settings.
...
A stepped-wedge cluster randomized trial evaluated whether pairing electronic decision support with routine medication reviews increases deprescribing of potentially inappropriate medications among older...
A systematic review and meta-analysis presented at the 2026 American College of Cardiology Scientific Session evaluated whether tafamidis was associated with improved survival in patients aged 80 years and...
Researchers compared high-dose versus standard-dose influenza vaccines in adults aged 65 to 79 years to determine whether enhanced immunogenicity translates into reduced severe clinical outcomes, including...
